Regenative Labs

Regenative Labs is a private, commercial-stage biotechnology company specializing in structural tissue allografts regulated under the FDA's 361 HCT/P pathway. The company leverages human birth tissue, primarily Wharton's Jelly from the umbilical cord, to create a portfolio of products (CryoText, SecreText, ProText, AmnioText) for orthopedic, sports medicine, and aesthetic applications. It operates with a B2B model, partnering directly with physicians and providers, and manufactures its products in an ISO Class 5 cleanroom facility. The company is actively generating revenue, publishing clinical case studies, and positioning itself in the growing market for regenerative alternatives to invasive surgery and opioids.

Proprietary processing and preservation of human birth tissue (Wharton's Jelly and amniotic membrane) into structural allografts under ISO Class 5 conditions, regulated as 361 HCT/Ps.

Regenative Labs competes in a crowded field of companies offering human birth tissue-derived allografts (e.g., from amniotic membrane, umbilical cord). Competitors range from large tissue banks to specialized regenerative medicine firms. Differentiation is based on processing methods, product claims, clinical support, physician relationships, and price.